NeoGenomics (NASDAQ:NEO) delivered solid fourth-quarter 2025 results, with consolidated revenue increasing 11% year over year to $190 million, driven by robust demand for its oncology-focused diagnostic testing services.
Full-year consolidated revenue grew 10% to $727 million, reflecting continued expansion in clinical services, including a 15% increase in clinical revenue (or 13% excluding the impact of the Pathline acquisition).
The company narrowed its fourth-quarter net loss by 36% to $10 million, while full-year net loss widened 37% to $108 million, largely due to ongoing operating expenses, strategic investments, and non-cash items.
Adjusted EBITDA swung to positive $13 million in the fourth quarter, up 13% from the prior year, and rose 9% for the full year to positive $43 million.
The results underscore NeoGenomics' positioning as a key player in precision oncology diagnostics, with growth fueled by higher test volumes—clinical volumes rose approximately 12% for the year—and adoption of advanced NGS and molecular testing.
The company has emphasized its comprehensive menu across the cancer care continuum, serving oncologists, pathologists, and hospitals with solutions that support targeted therapies and minimal residual disease (MRD) monitoring.